Search - tctmd.com

Displaying 41 - 60 of 144

Sort: Relevancy | Date

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

August 28, 2021

Colchicine in STEMI Fails to Reduce Infarct Size: COVERT-MI

News Daily News ESC 2021

Colchicine in STEMI Fails to Reduce Infarct Size: COVERT-MI

August 26, 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

News Conference News ESC 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

August 24, 2021

More Bleeding, Death With Ticagrelor Over Clopidogrel in Elderly Post-MI Patients: SWEDEHEART

News Conference News ESC 2020

More Bleeding, Death With Ticagrelor Over Clopidogrel in Elderly Post-MI Patients: SWEDEHEART

Yael L. Maxwell

September 08, 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

News Conference News ESC 2020

Chinese Data Back Anticoagulants to Prevent COVID-19 Thromboembolism

September 04, 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

News Conference News ESC 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

September 03, 2020

Acute MI Patients With Anemia May Require Fewer RBC Transfusions: REALITY

News Conference News ESC 2020

Acute MI Patients With Anemia May Require Fewer RBC Transfusions: REALITY

September 01, 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

News Conference News ESC 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Michael O'Riordan

August 31, 2020

Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC

News Conference News ESC 2020

Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC

August 31, 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

News Conference News ESC 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

August 31, 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

News Conference News ESC 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

August 30, 2020

Trimetazidine Safe but Not Protective Long-term After PCI

News Conference News ESC 2020

Trimetazidine Safe but Not Protective Long-term After PCI

August 30, 2020

News Conference News ESC 2020

Go With Aspirin Alone After TAVR When Anticoagulation Isn’t Needed: POPular TAVI

August 30, 2020

More Than Half of Patients See a GP in the 2 Weeks Before OHCA

News Conference News ESC 2020

More Than Half of Patients See a GP in the 2 Weeks Before OHCA

Yael L. Maxwell

August 28, 2020

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

September 06, 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

News Conference News ESC 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Yael L. Maxwell

September 03, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

Lifelong Exposure to Lower LDL and BP Linked With Big Reduction in CVD Events

News Conference News ESC 2019

Lifelong Exposure to Lower LDL and BP Linked With Big Reduction in CVD Events

Michael O'Riordan

September 02, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.